为探讨131I治疗甲亢的临床应用价值，采用常规手法触诊对甲状腺估重，按每g甲状腺实际吸收剂量计算131I的给药剂量，给药方式均为一次口服。服药后3个月复查，包括症状、体征及血清垂体-甲状腺轴激素。结果表明，105例中基本治愈者80例（76.2%），基本治愈但有早期甲减者16例（15.2%），本组131I一次治疗的有效率为91.4%；复发者9例（8.6%），经第二次治疗后病情亦得到控制。说明131I治疗Graves甲亢的治愈率高、复发率低、简便易行，若运用131I的治疗剂量合适，可以将早期甲减发病率控制在可接受的范围内。%To observe the clinical value of 131I in the treatment of hyperthyroidism. The weight of the thyroid was evaluated by palpation, 131I was taken orally by one dose method. The dose was calculated by actual absorption of 131I/per gram of thyroid. 3—6 months after drug administration, the symptom, clinical manifestation and the serum hormone of the pituitary-hypothyroid axis were observed. In 105 cases, 80(76.2%) were nearly recovered, among them 16(15.2%) had hypothyroidism in the early period. The allover recovering rate was 91.4% in one dose, but 9(8.6%) were recurred and can be controlled at a second dose. Therefore 131I for the hyperthyroidism had a high recovering rate, low recurring rate and was very convenient. If the dose at an optimal range was controlled. The occurrence of hypothyroidism can be reduced to the acceptable level.
展开▼
